Aliskiren as an adjunct therapy for atypical hemolytic uremic syndrome

Richard A. Plasse, Robert Nee, Stephen W. Olson*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Direct renin inhibitors (DRIs) block the activation of the alternative complement pathway in vitro and could be a treatment option for refractory hypertension in atypical hemolytic uremic syndrome (aHUS). A 20-year-old male presented with primary aHUS complicated by end-stage renal disease and refractory malignant hypertension despite being on five antihypertensive medications at maximum dose. Only a partial response was achieved with aliskiren and eculizumab, but after increasing aliskiren to a supratherapeutic dose, antihypertensive medication was reduced, platelets increased, C3 increased and epoetin alfa requirement decreased. DRI may be an adjunct treatment for malignant hypertension associated with aHUS.

Original languageEnglish
Pages (from-to)39-41
Number of pages3
JournalClinical Kidney Journal
Issue number1
StatePublished - 21 Apr 2019
Externally publishedYes


  • alternative complement pathway
  • atypical hemolytic uremic syndrome
  • direct renin inhibitors
  • malignant hypertension


Dive into the research topics of 'Aliskiren as an adjunct therapy for atypical hemolytic uremic syndrome'. Together they form a unique fingerprint.

Cite this